2-[1'(S)-(tert-butyloxycarbonylamino)-2'(S)-methylbutyl]-4(S)-(methoxycarbonyl)-5-methyloxazoline | 910468-14-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[1'(S)-(tert-butyloxycarbonylamino)-2'(S)-methylbutyl]-4(S)-(methoxycarbonyl)-5-methyloxazoline
• CAS: 910468-14-3
• 化学式: C₁₆H₂₈N₂O₅
• 分子量: 328.409
• InChiKey: GXKWHIZKLHNZHL-USZNOCQGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.28
• 重原子数：
  23.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  86.22
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  2-[1'(S)-(tert-butyloxycarbonylamino)-2'(S)-methylbutyl]-4(S)-(methoxycarbonyl)-5-methyloxazoline 在 盐酸 、 4-二甲氨基吡啶 、 三氯溴甲烷 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 74.0h， 生成 (4S,18S)-4,18-di((S)-sec-butyl)-7-methyl-6-oxa-13,20-dithia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.15,8.112,15]tetracosa-1(21),5(23),7,12(24),14,19(22)-hexaene-2,9,16-trione
  参考文献：
  名称：

  Synthesis of a Microcystis aeruginosa predicted metabolite with antimalarial activity

  摘要：

  The synthesis of a Microcystis aeruginosa predicted metabolite analog of aerucyclamide B was performed. This hexacyclopeptide was obtained from three heterocyclic building blocks by a convergent macrocycle-assembly methodology. The compound exhibited good in vitro antiplasmodial activity (IC50: 0.18 mu M, K1, cholorquine resistant strain). (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.028
• 作为产物：
  描述：

  Boc-Ile-Thr-OMe 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以95%的产率得到2-[1'(S)-(tert-butyloxycarbonylamino)-2'(S)-methylbutyl]-4(S)-(methoxycarbonyl)-5-methyloxazoline
  参考文献：
  名称：

  Synthesis of a Microcystis aeruginosa predicted metabolite with antimalarial activity

  摘要：

  The synthesis of a Microcystis aeruginosa predicted metabolite analog of aerucyclamide B was performed. This hexacyclopeptide was obtained from three heterocyclic building blocks by a convergent macrocycle-assembly methodology. The compound exhibited good in vitro antiplasmodial activity (IC50: 0.18 mu M, K1, cholorquine resistant strain). (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.028

文献信息

• Rational Design of Bacitracin A Derivatives by Incorporating Natural Product Derived Heterocycles
  作者：Björn Wagner、Dirk Schumann、Uwe Linne、Ulrich Koert、Mohamed A. Marahiel

  DOI：10.1021/ja062906w

  日期：2006.8.1

  Heterocycles display common structural motifs in nonribosomally produced peptides with an enormous impact on their bioactivity. In the case of the branched cyclic Bacitracin A, the thiazoline moiety is manufactured during NRPS peptide chain elongation. Here we describe a method to selectively alter the heterocyclic metal binding subunit of Bacitracin A by the synthesis of heterocyclic building blocks that were successfully coupled to the linear decapeptide and subsequently cyclized using the excised bacitracin PCP-TE bidomain. Utilization of this cyclase allowed the first generation of branched cyclic bacitracin derivatives containing thiazole and oxazoles. The generated bacitracin derivatives showed bactericidal activity, indicating the possibility of altering the biological important heterocyclic subunit and overcoming existing limitations for the application of bacitracin.